RAS like estrogen regulated growth inhibitorGenealiases: []
Q-omics provides the consensus-scored RERG profile across patient tissues and cancer cell-line models. RERG expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RERG is differentially expressed in 16, with the highest sampling consensus in BLCA. Additionally, RERG protein abundance shows 24,878 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight ACC, BLCA, and LUAD as cancer lineages where RERG shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RERG — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RERG survival associations across molecular data types. RERG RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RERG RNA expression–survival associations across cancer types. High RERG expression shows unfavorable associations in UVM and STAD, but favorable associations in ACC, HNSC, KIRC and BRCA. The ACC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RERG RNA expression.
This table summarizes RERG tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 8. The strongest signals are observed in BLCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for RERG. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RERG shows lower tumor expression in BLCA, THCA, LUAD, COAD, UCEC and LUSC. The BLCA box plot shows higher RERG RNA expression in normal versus tumor tissue (log2 FC = −1.861, t-test p < 0.001).
This table shows molecular features associated with RERG in patient tissues and cancer cell lines. In patient samples, RERG shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, RERG RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUSC, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BREAST.
